How big is the breast cancer core needle biopsy market?

The market size of the breast cancer core needle biopsy is estimated at USD 1 billion in 2027.

How is the breast cancer core needle biopsy industry projected to perform over the next decade?

Breast Cancer Core Needle Biopsy Market size was more than USD 965.9 million in 2026 and is set to grow at a 4.66% CAGR between 2027 and 2036, reaching USD 1.52 billion by 2036.

How are rising breast cancer screening and diagnosis volumes influencing the breast cancer core needle biopsy market?

Higher screening activity is increasing referrals for image-guided tissue diagnosis, encouraging hospitals to expand biopsy capacity and standardize core needle biopsy to efficiently manage growing diagnostic workloads.

Why are healthcare providers investing in advanced ultrasound-guided biopsy technologies?

Improved imaging guidance and molecular diagnostic capabilities enhance sampling accuracy, reduce repeat procedures, and support more informed treatment planning, making advanced biopsy systems a higher-priority investment for healthcare providers.

Why do Hospitals & Diagnostic Laboratories dominate the breast cancer core needle biopsy market?

Hospitals & Diagnostic Laboratories accounted for 63% of the market in 2026, supported by integrated imaging, biopsy, pathology, and follow-up workflows that enable efficient diagnosis and clinical decision-making.

Why is CT-based Breast Biopsy the fastest-growing technology segment?

CT-based Breast Biopsy is expanding quickly because it supports precise anatomical localization in complex cases where lesion visualization or access is more challenging with conventional guidance techniques.

Why is North America the largest market for breast cancer core needle biopsy?

North America accounts for 49.04% share, supported by established imaging pathways, widespread image-guided biopsy access, and strong integration into routine diagnostic decision-making.

What is supporting Asia Pacific growth in this biopsy market?

Asia Pacific is growing at 5.36% CAGR due to improving diagnostic access, rising minimally invasive procedures, and expanding imaging and hospital capabilities.

Who are the major participants shaping the breast cancer core needle biopsy landscape?

Major companies in the breast cancer core needle biopsy market include Hologic, Inc. (United States), Becton, Dickinson and Company (United States), Cook Medical Incorporated (United States), Argon Medical Devices, Inc. (United States), Leica Biosystems Nussloch GmbH (Germany), Merit Medical Systems, Inc. (United States), Mammotome (Devicor Medical Products, Inc.) (United States), STERYLAB S.r.l. (Italy), Olympus Corporation (Japan).